视网膜下基因治疗X连锁视网膜劈裂症的I期临床试验
这项研究向5至18岁X连锁视网膜劈裂症患者单眼视网膜下注射scAAV8-hRS1,主要终点为52周安全性。12例患者中未报告3级及以上不良事件或眼内炎症,治疗眼BCVA平均提高10.8个字母,SS-OCT显示所有治疗眼黄斑劈裂腔在13周内闭合,支持进一步临床测试。
要点
- 12例患者单眼接受scAAV8-hRS1视网膜下注射,52周内未报告3级及以上不良事件或眼内炎症。
- 治疗眼BCVA平均提高10.8个字母,未治疗眼提高2.4个字母;所有治疗眼黄斑劈裂腔在13周内闭合。
- 治疗眼中心视网膜厚度平均变化-437.7 μm,未治疗眼-17.2 μm;9例治疗眼外层视网膜在52周连续。
核心结论
- 12例X连锁视网膜劈裂症患者接受scAAV8-hRS1视网膜下注射后,未报告3级及以上不良事件或眼内炎症,支持进一步临床测试。
研究设计与样本
- 单次视网膜下注射scAAV8-hRS1的剂量递增与剂量扩展研究,纳入5至18岁X连锁视网膜劈裂症患者12例。
- 剂量递增阶段两个队列各3例,剂量分别为7.5×10^10或1×10^11载体基因组;剂量扩展阶段每个队列再纳入3例。
- 主要终点为注射后52周内的安全性,次要终点包括BCVA、SS-OCT视网膜结构、全视野ERG及微视野 macular sensitivity 的变化。
主要发现
- 52周内共报告56例次不良事件,无患者报告3级及以上不良事件或眼内炎症。
- 1例患者治疗眼在术后第1周观察到黄斑裂孔。
- 第52周BCVA平均提高:治疗眼10.8个字母,未治疗眼2.4个字母。
- SS-OCT显示所有12例治疗眼黄斑劈裂腔在13周内闭合。
- 第52周中心视网膜厚度平均变化:治疗眼-437.7 μm,未治疗眼-17.2 μm;9例治疗眼外层视网膜连续。
临床怎么用
- 该I期结果提示scAAV8-hRS1视网膜下注射在X连锁视网膜劈裂症患者中安全性可接受,支持后续临床测试。
- 治疗眼BCVA提高及黄斑劈裂腔闭合的初步疗效信号需在进一步临床试验中验证。
局限性
- 研究为小样本I期试验,共12例患者,未设对照,疗效结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: X-linked retinoschisis is a recessive disease characterized by progressive macular degeneration and vision loss due to pathogenic variation in RS1. METHODS: We administered a single subretinal injection of an AAV8 vector containing human RS1 complementary DNA (scAAV8-hRS1) into one eye of patients 5 to 18 years of age who had X-linked retinoschisis. The primary end point was safety during the 52-week period after injection. Secondary end points included the change from baseline to week 52 in the best corrected visual acuity (BCVA), retinal structure (assessed with swept-source optical coherence tomography; SS-OCT), the function of photoreceptor and bipolar cells (assessed with full-field electroretinography), and macular sensitivity to light (assessed with microperimetry). RESULTS: A total of 12 patients were enrolled. The dose-escalation phase included two cohorts of 3 patients each who received scAAV8-hRS1 at a dose of 7.5×1010 or 1×1011 vector genomes. In the dose-expansion phase, 3 additional patients were enrolled in each cohort. Overall, 56 adverse events were reported during the 52 weeks after surgery. No patient was reported to have an adverse event of grade 3 or higher or ocular inflammation. A macular hole in the treated eye was observed at week 1 in 1 patient. The mean increase at week 52 in the BCVA was 10.8 letters among the treated eyes and 2.4 letters among the untreated eyes. SS-OCT imaging showed closure of the macular schisis cavity by week 13 in the treated eye in all 12 patients. The mean change at week 52 in central retinal thickness was -437.7 μm among the treated eyes and -17.2 μm among the untreated eyes; the outer retinal layers in the treated eyes of 9 patients were continuous at week 52. No clinically meaningful changes in the function of photoreceptor and bipolar cells or macular retinal sensitivity were observed in the treated eyes. CONCLUSIONS: In this study of subretinal gene therapy with scAAV8-hRS1 in 12 patients with X-linked retinoschisis, there were no reports of adverse events of grade 3 or higher or ocular inflammation. Further clinical testing of scAAV8-hRS1 is warranted. (Funded by the National Natural Science Foundation of China and others; Chinese Clinical Trial Registry number, ChiCTR2300076682.).
引用
- Liang L, She K, Ren C, et al. Subretinal Gene Therapy for X-Linked Retinoschisis. N Engl J Med. 2026. PMID: 42269152. doi:10.1056/NEJMoa2515953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。